PETX News and Press, Aratana Therapeutics Inc. From 03/12/19

Aratana Therapeutics (NASDAQ: PETX ): Q4 GAAP EPS of -$0.18. More news on: Aratana Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

LEAWOOD, Kan. , March 12, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, announced its fourth quarter and full year 2018 financial results and re...

LEAWOOD, Kan. , Feb. 12, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, will host a live conference call on Tuesday, March 12, 2019 at 4:30 p....

Aratana Therapeutics (NASDAQ: PETX ) appoints  Rhonda Hellums as Chief Financial Officer (CFO) and Treasurer effective February 1. More news on: Aratana Therapeutics, Healthcare stocks news, Read more ...

LEAWOOD, Kan. , Feb. 4, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the appointment of Rhonda Hellums as Chief Financial Off...

Aratana suffered a 26.55% decline on Friday, January 11th, as a downgrade from Stifel ( Aratana down 27% as Stifel softens view ) was said to have prompted the selloff. Perhaps more impactful, was the 13D filing which showed Engaged Capital has reduced their position to roughly 4.1% shares o...

NEW YORK, Jan. 25, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Immunomedics, Inc. (NASDAQ:IMMU), Diamondrock Hospitality Company (NYSE:D...